Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Recombinant human collagen gel dressing is a topical wound care product designed to promote healing in partial-thickness (second-degree) burns. It consists of collagen produced through recombinant DNA technology, which mimics the structure and function of natural human collagen without the risks associated with animal-derived products, such as immunogenicity or pathogen transmission. The gel formulation provides a moist wound environment, facilitates cell migration and proliferation, and serves as a scaffold for tissue regeneration. It is being evaluated in clinical trials for its efficacy and safety compared to traditional biological dressings like gene-transfected pigskin.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on recombinant human collagen gel dressing.